NMTC Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Product Revenue: Increased 907% to $2.7 million in Q4 2025 from $0.3 million in Q4 2024. For the full fiscal year, product revenue rose 163% to $9.1 million from $3.5 million.

License Revenue: $3 million in fiscal 2025, up from zero in fiscal 2024, attributed to an expanded distribution agreement with Zimmer Biomet.

Gross Profit: Q4 product gross profit was $1.5 million (55.8% margin), up from $0.1 million (51.8% margin) in Q4 2024. Full-year gross profit was $5.1 million (56.5% margin), compared to $1.1 million (31.3% margin) in fiscal 2024.

Operating Expenses: Decreased 2% to $2.9 million in Q4 2025; full-year operating expenses fell 5% to $12.4 million.

Net Loss: Improved by 52% to $1.6 million ($0.03 per share) in Q4 2025, and by 71% to $3.6 million ($0.09 per share) for the full year.

Cash Position: Cash and equivalents rose to $6.6 million from $1.5 million year-over-year, with working capital increasing to $7.9 million.

2Strategic Updates and Business Highlights

FDA Approvals: Received 510(k) clearance for the OneRF trigeminal nerve ablation system and advanced development of spinal cord stimulation electrodes.

New Product Development: Initiated programs for basivertebral nerve ablation and drug delivery systems, with significant physician interest noted.

Partnerships: Engaged with potential partners for drug delivery and pain management technologies, while continuing to strengthen the relationship with Zimmer Biomet.

Intellectual Property: Expanded patent portfolio with 17 issued and pending patents, including a European patent for a temperature control probe.

3Forward Guidance and Outlook

Financial Guidance: Anticipated guidance for fiscal 2026 will be provided after receiving forecasts from Zimmer Biomet.

Commercial Readiness: Plans to be ready for commercial launch of preclinical drug delivery offerings and to develop pathways for FDA clearance in 2026.

Growth Prospects: Confident in the revenue potential from the OneRF ablation system and ongoing discussions for international sales.

4Bad News, Challenges, or Points of Concern

NASDAQ Compliance: Received a 180-day extension to regain compliance with NASDAQ's minimum bid price rule, indicating ongoing stock price pressures.

Operational Challenges: Some delays in additional procedures due to equipment availability at treatment centers, which could impact short-term revenue generation.

Reimbursement Landscape: While current adoption is strong, the reimbursement environment remains complex, with no specific codes for some procedures, which could pose risks as the company scales.

5Notable Q&A Insights

Trigeminal Nerve Ablation: Expectation of more procedures before year-end, contingent on equipment availability.

Drug Delivery Orders: Anticipated additional orders from a large pharmaceutical partner mid-year for preclinical testing.

Reimbursement Strategies: The company is navigating a complex reimbursement landscape but has not faced significant barriers to adoption thus far.

Strategic Partnerships: Discussions with potential partners for pain management technologies are ongoing, with confidence in reaching agreements. Overall, NMTC reported a strong fiscal year 2025 with significant revenue growth and strategic advancements, while also facing challenges related to compliance and operational execution.